← All trials
NCT04366739
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 29, 2020
- Primary completion
- Aug 30, 2020
- Completion date
- Sep 30, 2020
- First posted
- Apr 29, 2020
- Last posted
- Apr 29, 2020
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Centre Hospitalier St AnneLead sponsor
- University of ParisCollaborator
- Service Hospitalo-Universitaire - GHU PARIS Psychiatrie & NeurosciencesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.